How will this new drug impact profits and inevitably the PMU mares and their foals?
DUAVEE®, the Premarin® ― bazedoxifene combination therapy for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis in women who have not undergone hysterectomy was FDA-approved in October 2013 amid speculation regarding its safety profile and Pfizer/Wyeth’s lengthy struggle to gain approval.
Pfizer anticipates that DUAVEE® will be available in the U.S. in the first quarter of 2014.
This is the first approval of DUAVEE® in any country worldwide ― an approval of a combination drug with the component bazedoxifene yet to receive FDA approval on its own ― its approval is valid only in combination with Premarin®, at least in the US ― a conundrum in itself and worthy of further debate.
Some market analysts estimate DUAVEE®’s peak sales to reach $200 million (USD)/annum. 
DUAVEE® will be sold as a…
View original post 801 more words